S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:APEN

Apollo Endosurgery Stock Forecast, Price & News

$5.95
+0.39 (+7.01 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.04
Now: $5.95
$6.07
50-Day Range
$3.78
MA: $4.72
$6.31
52-Week Range
$1.24
Now: $5.95
$7.96
Volume270,729 shs
Average Volume1.25 million shs
Market Capitalization$154.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands; and Orbera Coach, a digital and remotely delivered aftercare program. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Apollo Endosurgery logo

Headlines

Apollo Endosurgery's Earnings: A Preview
February 24, 2021 |  benzinga.com
Apollo Endosurgery Announces CEO Transition
February 8, 2021 |  finance.yahoo.com
Apollo Gets OK from FDA
December 16, 2020 |  baystreet.ca
Where Do Hedge Funds Stand On Apollo Endosurgery (APEN)?
December 2, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APEN
CUSIPN/A
Phone512-279-5100
Employees217
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$50.71 million
Book Value$0.10 per share

Profitability

Net Income$-27,430,000.00

Miscellaneous

Market Cap$154.60 million
Next Earnings Date5/3/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

546th out of 1,972 stocks

Surgical & Medical Instruments Industry

53rd out of 169 stocks

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$5.95
+0.39 (+7.01 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APEN News and Ratings via Email

Sign-up to receive the latest news and ratings for APEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions

Is Apollo Endosurgery a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Apollo Endosurgery stock.
View analyst ratings for Apollo Endosurgery
or view top-rated stocks.

What stocks does MarketBeat like better than Apollo Endosurgery?

Wall Street analysts have given Apollo Endosurgery a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Apollo Endosurgery wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Apollo Endosurgery?

Apollo Endosurgery saw a decline in short interest during the month of January. As of January 29th, there was short interest totaling 168,200 shares, a decline of 47.9% from the January 14th total of 323,000 shares. Based on an average daily trading volume, of 194,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.1% of the shares of the stock are sold short.
View Apollo Endosurgery's Short Interest
.

When is Apollo Endosurgery's next earnings date?

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Apollo Endosurgery
.

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery, Inc. (NASDAQ:APEN) announced its quarterly earnings results on Tuesday, August, 4th. The biotechnology company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.03. The biotechnology company had revenue of $5.64 million for the quarter, compared to analyst estimates of $4.81 million.
View Apollo Endosurgery's earnings history
.

How has Apollo Endosurgery's stock been impacted by COVID-19 (Coronavirus)?

Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APEN shares have increased by 188.1% and is now trading at $5.95.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for APEN?

1 Wall Street analysts have issued 1-year target prices for Apollo Endosurgery's shares. Their forecasts range from $5.00 to $5.00. On average, they expect Apollo Endosurgery's share price to reach $5.00 in the next twelve months. This suggests that the stock has a possible downside of 16.0%.
View analysts' price targets for Apollo Endosurgery
or view top-rated stocks among Wall Street analysts.

Who are Apollo Endosurgery's key executives?

Apollo Endosurgery's management team includes the following people:
  • Mr. Todd Newton, CEO & Director (Age 58, Pay $435.89k)
  • Ms. Stefanie L. Cavanaugh, CFO, Treasurer & Sec. (Age 56, Pay $329.02k)
  • Mr. Bret Schwartzhoff, VP, US Sales & Global Marketing (Age 48, Pay $342.16k)
  • Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
  • Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
  • Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
  • Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner
  • Dr. Christopher J. Gostout, Co-Founder & Chief Medical Officer (Age 70)
  • Mr. Sydney Chung M.D., Co-Founder and Innovation Partner
  • Dr. Pankaj J. Pasricha MBBS, M.D., FACP, Co-Founder

Who are some of Apollo Endosurgery's key competitors?

What other stocks do shareholders of Apollo Endosurgery own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Who are Apollo Endosurgery's major shareholders?

Apollo Endosurgery's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.02%), Northern Trust Corp (0.97%), Renaissance Technologies LLC (0.87%), BlackRock Inc. (0.15%) and University of Texas Texas AM Investment Managment Co. (0.06%). Company insiders that own Apollo Endosurgery stock include Neil Gagnon, R Kent Mcgaughy Jr and Todd Newton.
View institutional ownership trends for Apollo Endosurgery
.

Which major investors are selling Apollo Endosurgery stock?

APEN stock was sold by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co., and Northern Trust Corp.
View insider buying and selling activity for Apollo Endosurgery
or view top insider-selling stocks.

Which major investors are buying Apollo Endosurgery stock?

APEN stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Renaissance Technologies LLC, and BlackRock Inc.. Company insiders that have bought Apollo Endosurgery stock in the last two years include Neil Gagnon, R Kent Mcgaughy Jr, and Todd Newton.
View insider buying and selling activity for Apollo Endosurgery
or or view top insider-buying stocks.

How do I buy shares of Apollo Endosurgery?

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $5.95.

How much money does Apollo Endosurgery make?

Apollo Endosurgery has a market capitalization of $154.60 million and generates $50.71 million in revenue each year. The biotechnology company earns $-27,430,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Apollo Endosurgery have?

Apollo Endosurgery employs 217 workers across the globe.

What is Apollo Endosurgery's official website?

The official website for Apollo Endosurgery is www.apolloendo.com.

Where are Apollo Endosurgery's headquarters?

Apollo Endosurgery is headquartered at 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.